| About the author: |
O.B. Kuchmenko, V.O. Dziuba, S.I. Savosko, T.V. Kozytska, O.Yu. Kvasko, A.V. Gumenyuk, T.M. Oliinyk |
| Heading |
EXPERIMENTAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
Doxorubicin is one of the most effective drugs, which is often used in clinical practice. The purpose of this work was to study the structural basis of the doxorubicin toxic effects on the heart, liver and kidneys and under the influence of metabolic drugs. Results of the histological and morphometric studies indicate the potential cytoprotective properties of the studied metabolic drugs – ubiquinone-10, a complex of precursors and modulator of ubiquinone biosynthesis (vitamin E, methionine, paraoxybenzoic acid and magnesium) and tiotriazolini in the conditions of experimental doxorubicin cardiomyopathy (the cumulative dose of doxorubicin is 15 mg/kg) and can serve as an experimental justification for their feasibility as a protective agents in clinical practice. |
| Tags |
doxorubicin, heart, liver, kidney, ubiquinone, thiotriazolini |
| Bibliography |
- Dziuba VO, Kuchmenko OB, Yakoviichuk OV. Stan prooxydantno-antyoxydanynoi rivnovahy ta aktyvnist enzymiv tsykly Krebsa u tkanynakh pechinky, sernsya i nyrok za dii riznykh kumulyanyvnykh doz doksorubitsynu. Bilolhia tvaryn. 2018; 20(1): 28-39. doi: 10.15407/animbiol20.01.028. [in Ukrainian]
- Dziuba VO, Kuchmenko OB, Yakoviichuk OV. Vplyv fiziolohichno aktyvnykh spoluk metabolichnoi dii na stan prooksydantno-antyoksydantnoi rivnovahy na aktyvnist enzymiv tsyklu krebsa v tkanynakh sertsia ta pechinky shchuriv za eksperymentalnoi doksorubitsynovoi kardiomiopatii. Naukovs zapysky NaUKMA. Biolohia ta ekolohia. 2018; 1: 28-33. [in Ukrainian]
- Mikulyak NI, Kinzirskaya YA. Eksperimentalnoe izuchenie pokazateley perekisnogo okisleniya lipidov pri vozdeystvii doksorubitsina i meksidola. Vestnik VolgGMU. 2011; 1(37): 101-3. [in Russian]
- Alves AC, Magarkar A, Horta M, Lima J, Bunker A, Nunes C, et al. Influence of doxorubicin on model cell membrane properties: insights from in vitro and in silico studies. Scientific reports. 2017; 7(1): 6343. doi: 10.1038/s41598-017-06445-z.
- Cardiff RD, Miller CH, Munn RJ. Manual hematoxylin and eosin staining of mouse tissue sections. Cold Spring Harb Protoc. 2014; 2014(6): 655-8. doi: 10.1101/pdb.prot073411.
- Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin cardiomyopathy. Cardiology. 2010; 115(2): 155-62. doi: 10.1159/000265166.
- Chegaev K, Riganti C, Rolando B, Lazzarato L, Gazzano E, Guglielmo S, Ghigo D, Fruttero R, Gasco A. Doxorubicin-antioxidant co-drugs. Bioorg Med Chem Lett. 2013; 23(19): 5307-10. doi: 10.1016/j.bmcl.2013.07.070.
- Jablonska-Trypuc A, Kretowski R, Kalinowska M, Swiderski G, Cechowska-Pasko M, Lewandowski W. (2018). Possible mechanisms of the prevention of doxorubicin toxicity by cichoric acid-antioxidant nutrient. Nutrients. 2018; 10(1): 44. doi: 10.3390/nu10010044.
- Leal AD, Kadakia KC, Looker S, Hilger C, Sorgatz K, Anderson K, et al. Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy. Support Care Cancer. 2014; 22: 1313–17. doi: 10.1007/s00520-013-2089-8.
- Mamidi RN, Weng S, Stellar S, Wang C, Yu N, Huang T, et al. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products? Cancer Chemother Pharmacol. 2010; 66(6): 1173-84. doi: 10.1007/s00280-010-1406-x.
- Martinel Lamas DJ, Nicoud MB, Sterle HA, Carabajal E, Tesan F, Perazzo, JC, et al. Selective cytoprotective effect of histamine on doxorubicin-induced hepatic and cardiac toxicity in animal models. Cell death discovery. 2015; 1: 15059. doi: 10.1038/cddiscovery.2015.59.
- Papeta N, Zheng Z, Schon EA, Brosel S, Altintas MM, Nasr SH, et al. Prkdc participates in mitochondrial genome maintenance and prevents Adriamycin-induced nephropathy in mice. J Clin Invest. 2010; 120(11): 4055-64. doi: 10.1172/JCI43721.
- Takiue K, Sugiyama H, Inoue T, Morinaga H, Kikumoto Y, Kitagawa M, et al. Acatalasemic mice are mildly susceptible to adriamycin nephropathy and exhibit increased albuminuria and glomerulosclerosis. BMC Nephrology. 2012; 13: 14. doi: 10.1186/1471-2369-13-14.
- Wang L, Chen Q, Qi H, Wang C, Wang C, Zhang J, Dong L. Doxorubicin-induced systemic inflammation is driven by upregulation of toll-like receptor TLR4 and endotoxin leakage. Cancer Res. 2016; 76(22): 6631-42. doi: 10.1158/0008-5472.CAN-15-3034.
- Zager RA, Johnson AC, Becker K. Plasma and urinary heme oxygenase-1 in AKI. J Am Soc Nephrol. 2012; 23(6): 1048-57. doi: 10.1681/ASN.2011121147.
|
| Publication of the article |
«World of Medicine and Biology» №4(74), 2020 year, 184-188 pages, index UDK 591.8 |
| DOI |
10.26724/2079-8334-2020-4-74-184-188 |
